For over a century, a diagnosis of Alzheimer’s disease has been widely regarded by the medical community and families alike as an irreversible, one-way street. However, a groundbreaking study published in late December 2025 by a collaborative team in Cleveland is challenging that long-held dogma, offering the first tangible “proof of principle” that the brain’s decline might not be permanent.
Researchers from Case Western Reserve University, University Hospitals, and the Louis Stokes Cleveland VA Medical Center have identified a critical biological failure at the heart of the disease: a dramatic drop in a cellular energy molecule known as NAD+. By restoring the balance of this molecule using an experimental drug, the team successfully reversed advanced Alzheimer’s pathology and fully restored cognitive function in animal models.
The energy crisis in the brain
The study, led by Dr. Kalyani Chaubey and senior author Dr. Andrew Pieper, reveals that while NAD+ levels naturally decline as we age, this depletion is significantly more severe in brains afflicted by Alzheimer’s. NAD+ acts as a “metabolic currency,” essential for DNA repair and maintaining the energy balance required for neurons to survive.
“When NAD+ falls below necessary levels, cells cannot effectively perform essential maintenance and survival functions,” Dr. Pieper explained. This energy failure makes the brain vulnerable to the toxic buildup of amyloid plaques and tau tangles, the hallmark “corrosion” of the disease.
From prevention to recovery
In experiments utilizing two distinct mouse models—one mimicking amyloid issues and the other focusing on tau protein—the researchers introduced a compound called P7C3-A20. Unlike standard over-the-counter supplements that can push NAD+ to potentially unsafe levels, this pharmacological agent helps cells maintain a healthy balance under stress without driving them into dangerous territory.
The results were described as “striking” by the team. Not only did the treatment block the onset of the disease in younger mice, but it also repaired structural damage and fully restored memory and learning in mice with advanced conditions. Notably, this recovery occurred even without directly targeting the amyloid plaques that most current drugs focus on.
Cautious optimism for the future
While the scientific community is heralded this as a “big step forward,” experts urge cautious optimism. Because the results have currently only been observed in animal models, they do not yet guarantee the same outcome for human patients.
“Alzheimer’s is a complex, multifactorial, uniquely human disease,” noted Dr. Pieper, emphasizing that human clinical trials are the critical next step.
For the millions of families currently living with the shadow of dementia, this research provides more than just data; it provides a new narrative. It suggests that the damaged brain may, under the right conditions, have the capacity to repair itself. As this technology moves toward commercialization and eventual human testing, Cleveland stands at the forefront of a potential revolution in how we treat—and perhaps one day cure—one of the world’s most devastating diseases.
